Study characteristics
Variable | Frequency | Percent (%) |
Year of publication | ||
2007–2009 | 70 | 24 |
2010–2012 | 45 | 16 |
2013–2015 | 73 | 25 |
2016–2018 | 72 | 25 |
2019–2020 | 29 | 10 |
Country | ||
USA | 143 | 49 |
UK | 33 | 11 |
Canada | 19 | 7 |
Australia | 12 | 4 |
France | 6 | 2 |
Germany | 5 | 2 |
N/A | 62 | 21 |
Study type | ||
N/A | 130 | 45 |
Qualitative | 68 | 24 |
Quantitative | 68 | 24 |
Mixed methods | 23 | 8 |
Study design/Manuscript type | ||
Editorial/Commentary | 89 | 31 |
Other | 28 | 10 |
Systematic review | 27 | 9 |
Surveys | 24 | 8 |
Other literature review | 20 | 7 |
Observational | 19 | 7 |
Randomized controlled trial | 19 | 7 |
Other type of review/report | 15 | 5 |
Interviews (structured or semi-structured) | 13 | 4 |
Multiple designs | 10 | 3 |
Case report | 8 | 3 |
Case series | 7 | 2 |
Policy statement | 6 | 2 |
Non-randomized experimental study | 1 | 0 |
Scoping review | 1 | 0 |
Meta-analysis | 1 | 0 |
Case-control study | 1 | 0 |
Trauma/Emergency specific | 263 | 91 |
Disparities in study enrollment addressed | 26 | 9 |
Pediatric focused | 42 | 15 |
Geriatric focused | 4 | 1 |
Outbreak related | 26 | 9 |
COVID-19 related | 3 | 1 |
Regulatory body discussed | ||
US Food and Drug Administration (FDA) | 119 | 41 |
US Department of Health and Human Services (HHS) | 42 | 15 |
EU/European Commission | 8 | 3 |
Department of Defense (DoD) | 9 | 3 |
National Institutes of Health (NIH) | 12 | 4 |
Special populations included or addressed | ||
Children | 52 | 18 |
Prisoners | 3 | 1 |
Pregnant women | 13 | 4 |
Mentally disabled persons | 3 | 1 |
Economically/Educationally disadvantaged | 9 | 3 |
Students | 8 | 3 |
Victims of violence | 19 | 7 |
DoD, Department of Defense; EU, European Union; FDA, Food and Drug Administration; N/A, not available; NIH, National Institutes of Health.